Found: 27
Select item for more details and to access through your institution.
Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience.
- Published in:
- Bone Marrow Transplantation, 1999, v. 24, n. 3, p. 265, doi. 10.1038/sj.bmt.1701871
- By:
- Publication type:
- Article
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL<sup>+</sup> cells.
- Published in:
- Oncogene, 2012, v. 31, n. 11, p. 1419, doi. 10.1038/onc.2011.328
- By:
- Publication type:
- Article
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
- Published in:
- Leukemia (08876924), 2002, v. 16, n. 12, p. 2349, doi. 10.1038/sj.leu.2402775
- By:
- Publication type:
- Article
Endothelial cell support of hematopoiesis is differentially altered by IL-1 and glucocorticoids.
- Published in:
- 1998
- By:
- Publication type:
- journal article
All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.
- Published in:
- 1997
- By:
- Publication type:
- journal article
Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein.
- Published in:
- Gene Therapy, 1998, v. 5, n. 4, p. 556, doi. 10.1038/sj.gt.3300602
- By:
- Publication type:
- Article
From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 8, p. 1757, doi. 10.1038/leu.2013.13
- By:
- Publication type:
- Article
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 10, p. 2254, doi. 10.1038/leu.2012.92
- By:
- Publication type:
- Article
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 5, p. 959, doi. 10.1038/leu.2011.355
- By:
- Publication type:
- Article
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
- Published in:
- Leukemia (08876924), 2009, v. 23, n. 8, p. 1500, doi. 10.1038/leu.2009.60
- By:
- Publication type:
- Article
Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
- Published in:
- 2009
- By:
- Publication type:
- Letter
The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
- Published in:
- Leukemia (08876924), 2007, v. 21, n. 7, p. 1481, doi. 10.1038/sj.leu.2404716
- By:
- Publication type:
- Article
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
- Published in:
- Leukemia (08876924), 2007, v. 21, n. 1, p. 93, doi. 10.1038/sj.leu.2404463
- By:
- Publication type:
- Article
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP).
- Published in:
- Leukemia (08876924), 2006, v. 20, n. 6, p. 1061, doi. 10.1038/sj.leu.2404236
- By:
- Publication type:
- Article
D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients.
- Published in:
- 2005
- By:
- Publication type:
- Letter
An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Histological features of acute hepatitis after imatinib mesylate treatment.
- Published in:
- 2003
- By:
- Publication type:
- Case Study
PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.
- Published in:
- Cell Death & Disease, 2013, v. 4, n. 10, p. 1, doi. 10.1038/cddis.2013.309
- By:
- Publication type:
- Article
Differential effect of interferon α on chronic myelogenous leukaemia and normal haematopoietic progenitors in a stromal cell co-culture context: role of the flt3 ligand.
- Published in:
- British Journal of Haematology, 2000, v. 109, n. 2, p. 382, doi. 10.1046/j.1365-2141.2000.01917.x
- By:
- Publication type:
- Article
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
- Published in:
- British Journal of Dermatology, 2012, v. 167, n. 5, p. 1138, doi. 10.1111/j.1365-2133.2012.11186.x
- By:
- Publication type:
- Article
Imatinib mesilate inhibits melanogenesis in vitro.
- Published in:
- 2006
- By:
- Publication type:
- Letter
NATURAL-KILLER CELL ACTIVITY AND CYTOGENETIC RESPONSE IN CHRONIC MYELOGENOUS LEUKAEMIA TREATED WITH α-INTERFERON.
- Published in:
- British Journal of Haematology, 1991, v. 78, n. 4, p. 585, doi. 10.1111/j.1365-2141.1991.tb04502.x
- By:
- Publication type:
- Article